FATE – Fate Therapeutics, Inc.
Fate Therapeutics, Inc.FATE
$1.63Name : Fate Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $186,278,624.00
EPSttm : -1.49
Fate Therapeutics, Inc.
$1.63
21.27%$0.285Float Short %
12.02
Margin Of Safety %
Put/Call OI Ratio
0.07
EPS Next Q Diff
EPS Last/This Y
0.38
EPS This/Next Y
0.15
Price
1.34
Target Price
5.44
Analyst Recom
2.36
Performance Q
28.85
Relative Volume
0.4
Beta
2.23
Ticker: FATE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-07 | FATE | 0.9998 | 0.27 | 10.00 | 8393 |
| 2025-05-08 | FATE | 1.04 | 0.26 | 0.00 | 8392 |
| 2025-05-09 | FATE | 1.035 | 0.26 | 0.00 | 8401 |
| 2025-05-12 | FATE | 1.06 | 0.26 | 0.00 | 8399 |
| 2025-05-13 | FATE | 1 | 0.26 | 0.00 | 8400 |
| 2025-05-14 | FATE | 0.9674 | 0.26 | 0.00 | 8394 |
| 2025-05-15 | FATE | 1.01 | 0.26 | 0.01 | 8396 |
| 2025-05-16 | FATE | 1.06 | 0.26 | 3.06 | 8418 |
| 2025-05-19 | FATE | 1.215 | 0.08 | 0.00 | 4855 |
| 2025-05-20 | FATE | 1.26 | 0.08 | 0.00 | 5165 |
| 2025-05-21 | FATE | 1.16 | 0.08 | 0.00 | 5165 |
| 2025-05-22 | FATE | 1.19 | 0.08 | 0.00 | 5167 |
| 2025-05-23 | FATE | 1.17 | 0.08 | 0.00 | 5167 |
| 2025-05-27 | FATE | 1.22 | 0.08 | 0.00 | 5229 |
| 2025-05-28 | FATE | 1.265 | 0.07 | 0.01 | 5305 |
| 2025-05-29 | FATE | 1.32 | 0.07 | 0.00 | 5448 |
| 2025-05-30 | FATE | 1.215 | 0.07 | 0.01 | 5467 |
| 2025-06-02 | FATE | 1.29 | 0.07 | 0.00 | 5506 |
| 2025-06-03 | FATE | 1.36 | 0.07 | 0.00 | 5774 |
| 2025-06-04 | FATE | 1.425 | 0.07 | 0.00 | 5787 |
| 2025-06-05 | FATE | 1.34 | 0.07 | 0.00 | 5876 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-07 | FATE | 1.00 | 19.3 | - | -1.46 |
| 2025-05-08 | FATE | 1.03 | 19.3 | - | -1.46 |
| 2025-05-09 | FATE | 1.04 | 19.3 | - | -1.46 |
| 2025-05-12 | FATE | 1.07 | 19.3 | - | -1.46 |
| 2025-05-13 | FATE | 1.00 | 19.3 | - | -1.46 |
| 2025-05-14 | FATE | 0.96 | 19.3 | - | -1.46 |
| 2025-05-15 | FATE | 1.01 | 19.3 | - | -1.46 |
| 2025-05-16 | FATE | 1.07 | 19.3 | - | -1.46 |
| 2025-05-19 | FATE | 1.22 | -3.3 | - | -1.25 |
| 2025-05-20 | FATE | 1.25 | -3.3 | - | -1.25 |
| 2025-05-21 | FATE | 1.16 | -3.3 | - | -1.25 |
| 2025-05-22 | FATE | 1.19 | -3.3 | - | -1.25 |
| 2025-05-23 | FATE | 1.17 | -3.3 | - | -1.25 |
| 2025-05-27 | FATE | 1.22 | -3.2 | - | -1.26 |
| 2025-05-28 | FATE | 1.26 | -3.2 | - | -1.26 |
| 2025-05-29 | FATE | 1.32 | -3.2 | - | -1.26 |
| 2025-05-30 | FATE | 1.21 | -3.2 | - | -1.26 |
| 2025-06-02 | FATE | 1.29 | -3.2 | - | -1.26 |
| 2025-06-03 | FATE | 1.36 | -3.2 | - | -1.26 |
| 2025-06-04 | FATE | 1.43 | -3.2 | - | -1.26 |
| 2025-06-05 | FATE | 1.34 | -3.2 | - | -1.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-07 | FATE | 0.32 | -14.20 | 15.06 |
| 2025-05-08 | FATE | 0.32 | -14.20 | 15.06 |
| 2025-05-09 | FATE | 0.32 | -14.20 | 15.06 |
| 2025-05-12 | FATE | 0.32 | -13.00 | 12.89 |
| 2025-05-13 | FATE | 0.32 | -13.00 | 12.89 |
| 2025-05-14 | FATE | 0.32 | -13.00 | 12.89 |
| 2025-05-15 | FATE | 0.32 | -13.00 | 12.89 |
| 2025-05-16 | FATE | 0.32 | -13.00 | 12.89 |
| 2025-05-19 | FATE | 0.32 | -10.91 | 12.46 |
| 2025-05-20 | FATE | 0.48 | -10.91 | 12.46 |
| 2025-05-21 | FATE | 0.48 | -10.91 | 12.46 |
| 2025-05-22 | FATE | 0.48 | -10.91 | 12.46 |
| 2025-05-23 | FATE | 0.48 | -10.91 | 12.46 |
| 2025-05-27 | FATE | 0.48 | -7.76 | 12.46 |
| 2025-05-28 | FATE | 0.48 | -7.76 | 12.02 |
| 2025-05-29 | FATE | 0.48 | -7.76 | 12.02 |
| 2025-05-30 | FATE | 0.48 | -7.76 | 12.02 |
| 2025-06-02 | FATE | 0.48 | -6.16 | 12.02 |
| 2025-06-03 | FATE | 0.48 | -6.16 | 12.02 |
| 2025-06-04 | FATE | 0.48 | -6.16 | 12.02 |
| 2025-06-05 | FATE | 0.48 | -6.16 | 12.02 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.32
Avg. EPS Est. Current Quarter
-0.34
Avg. EPS Est. Next Quarter
-0.32
Insider Transactions
0.48
Institutional Transactions
-6.16
Beta
2.23
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
16
Growth Score
34
Sentiment Score
43
Actual DrawDown %
98.9
Max Drawdown 5-Year %
-99.4
Target Price
5.44
P/E
Forward P/E
PEG
P/S
11.51
P/B
0.53
P/Free Cash Flow
EPS
-1.49
Average EPS Est. Cur. Y
-1.26
EPS Next Y. (Est.)
-1.12
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1318.93
Relative Volume
0.4
Return on Equity vs Sector %
-85
Return on Equity vs Industry %
-67.2
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.2
EBIT Estimation
Fate Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 181
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading